Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex, Inc. (ZYXI) is a Nevada-incorporated medical technology company that develops, manufactures, markets, and sells non-invasive medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. The ZYXI news feed on Stock Titan aggregates company-issued press releases and other coverage that reflect both its operating activities and its financial and regulatory developments.
News about Zynex often highlights its medical device portfolio and corporate events. Company announcements describe its efforts to provide devices that support pain management and rehabilitation and to advance patient monitoring technologies, including multi-parameter and laser-based pulse oximetry. Updates have included submissions of products such as the NiCO laser pulse oximeter for FDA 510(k) review and subsequent strategic decisions to seek commercialization partners through its Zynex Monitoring Solutions subsidiary.
Investors following ZYXI news will also see disclosures related to the company’s financial performance, liquidity, and capital structure. Recent press releases and SEC-related announcements have discussed revenue trends, the impact of a temporary payment suspension from Tricare, restructuring measures, and the company’s evaluation of strategic alternatives with the assistance of external financial advisors and a special committee of the board.
Regulatory and capital markets developments are another key theme in Zynex news. In December 2025, Zynex announced that it had voluntarily entered into Chapter 11 court-supervised financial restructuring and later reported that Nasdaq had determined to delist its common stock as a result of the Chapter 11 cases. These items, along with leadership changes and board appointments, appear in the news flow and provide context on governance and oversight.
By reviewing the ZYXI news page, readers can track company communications on product strategy, restructuring progress, leadership changes, and listing status. This consolidated view helps users understand how Zynex’s medical technology focus intersects with its financial and regulatory path over time.
Zynex, Inc. (NASDAQ: ZYXI) reported preliminary Q1 2022 revenue ranging from $30.5 to $31.5 million, reflecting a 26% year-over-year increase, and adjusted EBITDA of $3.0 to $4.0 million, an approximately 900% rise. The company maintains its full-year 2022 guidance of $150 to $170 million in revenue and adjusted EBITDA between $25 and $35 million. The pain management division achieved a 3% growth in orders year-over-year despite a reduced sales force. New product additions, including knee braces, boosted orders significantly, with the highest orders recorded in March 2022.
Summary not available.
Zynex reported strong financial results for Q4 and full year 2021, with a 63% increase in annual revenue to $130.3 million and a 58% rise in Q4 revenue to $40.4 million. Net income surged 398% in Q4 to $8.9 million, yielding a diluted EPS of $0.23. The company achieved its 6th consecutive year of profitability with a cash balance of $42.6 million. For 2022, revenue guidance is set between $150-$170 million, despite challenges in hiring sales representatives due to labor market conditions.
Zynex, a medical technology company, announced it does not expect material revenue changes in 2022 following United Healthcare's decision to switch its prescription coverage. CEO Thomas Sandgaard emphasized that most of Zynex's business comes from out-of-network coverage, minimizing the impact of this shift. The mutual decision to terminate the contract allows Zynex to continue offering its NexWave device as a non-addictive pain solution. A conference call will take place on February 24, 2022, to discuss fourth-quarter and full-year results.
Zynex, Inc. (Nasdaq: ZYXI) announced it will report its fourth quarter and full-year 2021 financial results on February 24, 2022. Management will host a conference call and webcast at 2:15 p.m. MT / 4:15 p.m. ET to discuss these results and provide a corporate update. The company specializes in non-invasive medical devices for pain management and rehabilitation. Interested participants can register for the webcast through the provided link.
Zynex, a medical technology company, announced the addition of post-operative and osteoarthritis knee braces to its product line, enhancing its offerings in pain and rehabilitation. With over 10.4 million knee injuries annually, these braces can reduce pain and improve mobility for patients. The company aims to diversify its revenue and has begun training its nationwide sales force on these new products, which are commonly reimbursed by health insurers. CEO Thomas Sandgaard expressed optimism for the expansion, indicating a strategic focus on orthopedic solutions.
Zynex, Inc. (NASDAQ: ZYXI) reported a strong performance in Q4 2021, achieving an 18% year-over-year order growth and an estimated revenue of $40.0 to $43.0 million. The company expects a significant increase in Adjusted EBITDA, estimating $12.5 to $13.5 million for Q4, marking a 280% year-over-year increase. For 2021, Zynex estimates total revenues between $130.0 and $133.0 million, a rise of 62% to 66% from 2020. The successful acquisition of Kestrel Labs and sales rep productivity enhancement are additional noteworthy achievements.
Zynex, Inc. (NASDAQ: ZYXI) has initiated enrollments in a clinical trial for its fluid monitoring system, CM-1500, aimed at enhancing performance characterization during apheresis blood donation. Conducted at Vitalant Research Institute, the trial will monitor changes in the device's patented Relative Index. The CM-1500 received FDA clearance in February 2020, and the company is focused on building clinical evidence for this technology. Zynex is also preparing for the next-generation device (CM-1600) FDA submission, reinforcing its commitment to innovate in non-invasive monitoring solutions.
Zynex, Inc. (NASDAQ: ZYXI) has filed for a utility patent for its innovative noninvasive sepsis monitor, following a provisional patent application in January 2021. The monitor aims to provide advanced warning of sepsis onset, which affects over 1.7 million adults in the U.S. annually and results in approximately 300,000 deaths. CEO Thomas Sandgaard highlighted the monitor's potential to improve patient outcomes by measuring conditions noninvasively and facilitating timely intervention.
Zynex, Inc. (NASDAQ: ZYXI) announced the submission of a 510(k) application to the FDA for its CM-1600 fluid monitoring system, enhancing the existing CM-1500 model. This next-generation device features wireless connectivity and aims to optimize fluid management in patients at risk of hemorrhagic events. CEO Thomas Sandgaard emphasized its potential for improved patient care. The FDA submission is a critical step in advancing the technology, which promises superior accuracy in monitoring before, during, and after surgeries.